The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal
Open accessAbstract
// Hae Kyung Lee 1 , Susan Finniss 1 , Simona Cazacu 1 , Efrat Bucris 2 , Amotz Ziv-Av 2 , Cunli Xiang 1 , Kevin Bobbitt 3 , Sandra A. Rempel 4 , Laura Hasselbach 5 , Tom Mikkelsen 5 Shimon Slavin 6 and Chaya Brodie 1,2 1 Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, 2 Everard and Mina Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel, 3 Department of Public Health Sciences, 4 Barbara Jane Levy Laboratory of Molecular Neuro-Oncology, 5 Eugene & Marcia Applebaum Laboratory of Invasion & Molecular Therapeutics and 6 The international center for Cell Therapy and Cancer Immunotherapy (CTCI), Tel Aviv, Israel Correspondence: Chaya Brodie, email: // Keywords : miRNA delivery, mesenchymal stem cells, glioma, exosomes Received : February 12, 2013 Accepted : February 27, 2013 Published : February 28, 2013 Abstract MicroRNAs (miRNAs) have emerged as potential cancer therapeutics; however, their clinical use is hindered by lack of effective delivery mechanisms to tumor sites. Mesenchymal stem cells (MSCs) have been shown to migrate to experimental glioma and to exert anti-tumor effects by delivering cytotoxic compounds. Here, we examined the ability of MSCs derived from bone marrow, adipose tissue, placenta and umbilical cord to deliver synthetic miRNA mimics to glioma cells and glioma stem cells (GSCs). We examined the delivery of miR-124 and miR-145 mimics as glioma cells and GSCs express very low levels of these miRNAs. Using fluorescently labeled miRNA mimics and in situ hybridization, we demonstrated that all the MSCs examined delivered miR-124 and miR-145 mimics to co-cultured glioma cells and GSCs via gap junction–dependent and independent processes. The delivered miR-124 and miR-145 mimics significantly decreased the luciferase activity of their respected reporter target genes, SCP-1 and Sox2, and decreased the migration of glioma cells and the self-renewal of GSCs. Moreover, MSCs delivered Cy3-miR-124 mimic to glioma xenografts when administered intracranially. These results suggest that MSCs can deliver synthetic exogenous miRNA mimics to glioma cells and GSCs and may provide an efficient route of therapeutic miRNA delivery in vivo .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells
Kosaka, N., Iguchi, H., Yoshioka, Y., Takeshita, F., Matsuki, Y., & Ochiya, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.107821 · Cited by 1,934
The microRNA miR-124 antagonizes the anti-neural REST/SCP1 pathway during embryonic CNS development
Visvanathan, J., Lee, S., Lee, B., Lee, J. W., & Lee, S.-K. (2007) · Genes & Development · doi:10.1101/gad.1519107 · Cited by 683
Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells
Spaeth, E., Klopp, A., Dembinski, J., Andreeff, M., & Marini, F. (2008) · Gene Therapy · doi:10.1038/gt.2008.39 · Cited by 579
Jansen, B. J. H., Gilissen, C., Roelofs, H., Schaap-Oziemlak, A., Veltman, J. A., Raymakers, R. A. P., Jansen, J. H., Kögler, G., Figdor, C. G., Torensma, R., et al. (2010) · Stem Cells and Development · doi:10.1089/scd.2009.0288 · Cited by 139
Cited by
Extracellular vesicles as tools and targets in therapy for diseases
Kumar, M. A., Baba, S. K., Sadida, H. Q., Marzooqi, S. A., Jerobin, J., Altemani, F. H., Algehainy, N., Alanazi, M. A., Abou-Samra, A.-B., Kumar, R., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01735-1 · Cited by 1,343
Effect of exosomal miRNA on cancer biology and clinical applications
Sun, Z., Shi, K., Yang, S., Liu, J., Zhou, Q., Wang, G., Song, J., Li, Z., Zhang, Z., & Yuan, W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0897-7 · Cited by 800
Therapeutically harnessing extracellular vesicles
Cheng, L., & Hill, A. F. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00410-w · Cited by 737
Neophytou, C. M., Panagi, M., Stylianopoulos, T., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13092053 · Cited by 456
Jin, J., Shi, Y., Gong, J., Zhao, L., Li, Y., He, Q., & Huang, H. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1177-1 · Cited by 365
Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy
Hmadcha, A., Martin-Montalvo, A., Gauthier, B. R., Soria, B., & Capilla-Gonzalez, V. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00043 · Cited by 341
Mesenchymal stem cell exosomes: a two-edged sword in cancer therapy
Vakhshiteh, F., Atyabi, F., & Ostad, S. N. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200036 · Cited by 281
Naseri, Z., Kazemi Oskuee, R., Jaafari, M. R., & Forouzandeh, M. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s182384 · Cited by 253
An updated role of microRNA-124 in central nervous system disorders: a review
Sun, Y., Luo, Z.-M., Guo, X.-M., Su, D.-F., & Liu, X. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00193 · Cited by 223
Therapeutic and Diagnostic Potential of Exosomes as Drug Delivery Systems in Brain Cancer
Avgoulas, D. I., Tasioulis, K. S., Papi, R. M., & Pantazaki, A. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051439 · Cited by 57
Metadata
- Authors
- Lee, H. K., Finniss, S., Cazacu, S., Bucris, E., Ziv-Av, A., Xiang, C., Bobbitt, K., Rempel, S. A., Hasselbach, L., Mikkelsen, T., Slavin, S., & Brodie, C.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2013-02-28
- Volume
- 4
- Issue
- 2
- Pages
- 346-361
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1523297072
- Cited by
- 230
- References
- 4
- FWCI
- 7.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.